SEARCH
Search Details
Terashita Yukayo
| Hokkaido University Hospital Division of Child Maternal and Female medicine | Assistant Professor |
Researcher basic information
■ Degree■ URL
researchmap URLホームページURL■ Various IDs
ORCID IDJ-Global ID■ Research Keywords and Fields
Research Field■ Educational Organization
- Master's degree program, Graduate School of Medicine
- Doctoral (PhD) degree program, Graduate School of Medicine
Research activity information
■ Papers- Trametinib Plus Azacitidine as Bridging Therapy to Hematopoietic Stem Cell Transplantation in an Infant With PTPN11‐Mutated Juvenile Myelomonocytic Leukemia
Hisato Segoe; Jutaro Abe; Shinsuke Hirabayashi; Risa Nakashima; Kazumi Oura; Yukayo Terashita; Yuko Cho; Daichi Sajiki; Hideki Muramatsu; Atsushi Manabe
Pediatric Blood & Cancer, 14 Oct. 2026
Scientific journal - Combined Treatment of Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed by Newborn Screening
Yuki Ueda; Shunsuke Hirabayashi; Satoshi Yamada; Sachiko Nakakubo; Midori Nakajima; Takeru Goto; Jutaro Abe; Yukayo Terashita; Atsushi Manabe; Torayuki Okuyama; Kiyoshi Egawa
19 May 2026, [Peer-reviewed] - Therapeutic Courses of Presumed Intracranial Immature Teratoma Diagnosed Based on Increased Alpha-Fetoprotein.
Shigeru Yamaguchi; Yukitomo Ishi; Michinari Okamoto; Sogo Oki; Ryosuke Sawaya; Hiroaki Motegi; Yukayo Terashita; Shinsuke Hirabayashi; Kentaro Nishioka; Takayuki Hashimoto; Hiromi Okada; Emi Takakuwa; Hidefumi Aoyama; Atsushi Manabe; Miki Fujimura
Journal of child neurology, 8830738261446144, 8830738261446144, 07 May 2026, [Peer-reviewed], [International Magazine]
English, Scientific journal, Intracranial immature teratoma (ImT) is one of the non-germinomatous germ cell tumors, and elevated serum alpha-fetoprotein (AFP) value is a crucial clinical diagnostic indicator of ImT. In this retrospective study conducted among patients diagnosed with intracranial ImT, diagnostic procedures, therapeutic courses, histopathologic diagnosis, and prognosis were reviewed. Among 106 patients with intracranial germ cell tumors, 11 were diagnosed with ImT and treated since 2000. ImT was diagnosed via biopsy or based on mild or moderate serum AFP elevation of 10-500 ng/mL. Complete remission via chemoradiotherapy was achieved in only 2 patients (18%); 5 patients (45%) suffered from growing disease during treatment; and 7 patients required salvage tumor resection. The 10-year progression-free and overall survival rates were 76.2% and 87.5%, respectively. The therapeutic courses of ImT varied. Notably, cases in which treatment was applied considering ImT were highly prone to experience growing disease during treatment. - Endocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study.
Naoya Kaneko; Shuntaro Morikawa; Megumi Endo; Nozomi Hishimura; Liu Zhitong; Takeshi Yamaguchi; Hisato Segoe; Jutaro Abe; Kazumi Oura; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Akie Nakamura; Yukitomo Ishi; Seishin Takao; Yuto Matsuo; Shigeru Yamaguchi; Takayuki Hashimoto; Atsushi Manabe
Endocrine journal, 10 Apr. 2026, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, Medulloblastoma, a common pediatric central nervous system disease, is managed with surgery, chemotherapy, and craniospinal irradiation (CSI) delivered with either X-rays or protons. Proton-beam CSI, introduced to protect the surrounding tissues, may reduce endocrine toxicity. In this single-institution retrospective observational study, we evaluated adverse endocrine events in 14 patients diagnosed with medulloblastoma before 13 years of age: 9 and 5 received X-ray and proton beam CSI, respectively. In the X-ray therapy group, the median age at diagnosis was 4.2 (range: 1.4-12.5) years, the median post-radiation follow-up was 19.5 (9.7-34.7) years, and the median CSI dose was 25.2 (23.4-36.0) Gy. The proton beam therapy group showed corresponding medians of 9.4 (5.3-11.7) years, 6.9 (5.4-8.1) years, and 23.4 (23.4-36.0) Gy. Five years after radiation therapy completion, the incidence of growth hormone deficiency was 44% (4/9) and 60% (3/5) in the X-ray and proton beam therapy groups, respectively. However, primary hypothyroidism and central hypothyroidism were exclusively observed in the X-ray therapy group, in 33% (3/9) and 11% (1/9) of patients. Given the short follow-up period for the proton beam therapy group, the difference in the occurrence rates of gonadal dysfunction and adrenal insufficiency is currently unknown. Our findings suggest that, at ≤5 years after the completion of radiation therapy, radiation-induced hypothyroidism was observed only in patients treated with X-ray therapy and not in those treated with proton beam therapy. Further studies with larger cohorts and longer follow-up periods are required to clarify this possible advantage and to refine radiation therapy protocols. - Proton Whole Lung Irradiation for a Patient With Metastatic Ewing Sarcoma.
Yusuke Imanaka; Sho Kurihara; Yukayo Terashita; Masataka Hasegawa; Hiroshi Taguchi; Seishin Takao; Shuhei Karakawa; Takayuki Hashimoto; Atsushi Manabe; Satoshi Okada; Yoko Mizoguchi
Pediatric blood & cancer, e70160, 22 Feb. 2026, [Peer-reviewed], [International Magazine]
English - Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study.
Kayoko Tao; Takako Yoshioka; Miho Kato; Kazuyuki Komatsu; Shinichi Tsujimoto; Kenichi Sakamoto; Kazuki Tanimura; Minako Sugiyama; Masahiro Sekiguchi; Yoshiko Nakano; Yoshihiro Otani; Yasushi Yatabe; Akihiko Yoshida; Hajime Okita; Junko Hirato; Kenichi Kohashi; Yukichi Tanaka; Shinji Kohsaka; Takashi Kubo; Kuniko Sunami; Makoto Hirata; Shuichi Tsutsumi; Hiroyuki Aburatani; Katsuyoshi Koh; Masahiro Hirayama; Shuhei Karakawa; Yukayo Terashita; Hiroyuki Fujisaki; Takeshi Yagi; Akihiro Yoneda; Shinji Mochizuki; Hiroyuki Shichino; Tatsuya Suzuki; Tetsuya Takimoto; Koichi Ichimura; Chitose Ogawa; Kimikazu Matsumoto; Hitoshi Ichikawa; Motohiro Kato
Cancer science, 117, 2, 522, 535, Feb. 2026, [Peer-reviewed], [International Magazine]
English, Scientific journal, To develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted from January 2022 to February 2023 in collaboration with the Japan Children's Cancer Group. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0-29 years with solid tumors. Genomic analysis used the TOP2 hybrid capture-enrichment system, targeting 737 and 455 genes in the DNA and RNA panels, along with allele-specific genome copy number alterations. A total of 210 patients from 50 institutions were enrolled across Japan (median age, 8 years; range, 0-25). Of these, 154 (77%) were enrolled at diagnosis or during/after initial treatment and 56 (27%) at disease progression or relapse. The TOP2 findings had great benefits in clarifying the diagnosis of pediatric solid tumors. Among the 204 patients with genomic results, 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%), respectively. Oncogenic fusions were noted in 45 (23%) patients. A copy number alteration was identified in at least one genomic region in 170 (83%) patients. Two patients exhibited a high tumor mutation burden. Seventeen (8%) patients harbored a germline pathogenic/likely pathogenic variant in cancer-predisposing genes. This study highlighted the feasibility of implementing a nationwide precision medicine platform and the clinical utility of the TOP2 system for pediatric cancers. The results support the integration of genomic data into the standard clinical care of pediatric patients with cancer, both at diagnosis and at relapse. - Endocrine dysfunction induced by anti-PD-1 antibody and tyrosine kinase inhibitor in a pediatric patient with renal cell carcinoma
Megumi Endo; Shuntaro Morikawa; Naoya Kaneko; Nozomi Hishimura; Liu Zhitong; Takeshi Yamaguchi; Atsushi Yamaguchi; Hisato Segoe; Jutaro Abe; Kazumi Oura; Yukayo Terashita; Yuko Cho; Shinsuke Hirabayashi; Atsushi Manabe
Clinical Pediatric Endocrinology, Japanese Society for Pediatric Endocrinology, 2026, [Peer-reviewed]
Scientific journal - Comprehensive Cancer Genomic Profiling and Germline Predisposition Analysis in Pediatric Cancer: Insights From the Hokkaido Pediatric Cancer Consortium, Japan
Yusuke Saito; Yukayo Terashita; Toraji Amano; Minako Sugiyama; Kazumi Oura; Masataka Hasegawa; Jutaro Abe; Shinsuke Hirabayashi; Yuko Cho; Shin Ariga; Kanako Hagio; Yoshihito Ohhara; Junko Kikuchi; Yukitomo Ishi; Shigeru Yamaguchi; Hiromi Kanno-Okada; Emi Takakuwa; Zen-Ichi Tanei; Yuka Shibata; Mio Mukainakano; Honami Fujita; Kanako C. Hatanaka; Yutaka Hatanaka; Akira Takebayashi; Yusuke Akane; Masaki Yamamoto; Takeo Sarashina; Shinya Tanaka; Takahiro Yamada; Ichiro Kinoshita; Atsushi Manabe
PEDIATRIC BLOOD & CANCER, 72, S850, S850, Dec. 2025
English - The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post‐Transplant Complications, Including Sinusoidal Obstruction Syndrome
Kazuki Takahashi; Shinsuke Hirabayashi; Masahiro Ueki; Masataka Hasegawa; Hiroki Ohata; Shunichiro Takezaki; Yukayo Terashita; Yuko Cho; Atsushi Manabe
Pediatric Blood & Cancer, Dec. 2025, [Peer-reviewed]
Scientific journal - Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors.
Ayako Chida-Nagai; Yukayo Terashita; Shinsuke Hirabayashi; Hirokuni Yamazawa; Yuko Cho; Atsushi Manabe
Pulmonary circulation, 15, 3, e70165, Jul. 2025, [Peer-reviewed], [International Magazine]
English, Scientific journal, Pulmonary hypertension (PH) is a severe complication observed in pediatric patients after hematopoietic cell transplantation or chemotherapy. A review of records at Hokkaido University Hospital (2014-2024) identified four cases of PH, each with different etiologies, including pulmonary arterial hypertension, pulmonary veno-occlusive disease, and microthromboembolism. Contributing factors included splenic atrophy, corticosteroid-responsive inflammation, and potential drug-induced vascular remodeling. Although transient PH usually resolves, late-onset PH emphasizes the need for long-term echocardiographic monitoring. These findings underscore the importance of individualized management, avoiding pulmonary vasodilators without proper evaluation, and addressing underlying conditions such as thrombotic microangiopathy or interstitial lung disease. - Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma
Jimei Zhao; Kohei Nakajima; Masahiro Ueki; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Mikako Ogawa; Atsushi Manabe
EJC Paediatric Oncology, 5, 100233, 100233, Elsevier BV, Jun. 2025, [Peer-reviewed]
Scientific journal - Ultrasonographic scoring system for SOS/VOD in pediatric hematopoietic stem cell transplant recipients.
Mutsumi Nishida; Shinsuke Hirabayashi; Takahito Iwai; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Ryosuke Sakano; Yukayo Terashita; Yuko Cho; Atsushi Manabe; Takanori Teshima
International journal of hematology, 26 Apr. 2025, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, Sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) is a serious complication following hematopoietic stem cell transplantation. It is more common in children, with an incidence of approximately 20% compared to 10% in adult patients. While the Hokkaido ultrasonography (US)-based scoring system (HokUS-10 and HokUS-6) has proven effective in diagnosing SOS/VOD in adults, its utility in children remains uncertain. This study evaluated the utility of the HokUS-10/6 scoring systems in diagnosing pediatric SOS/VOD (pSOS/VOD) in a cohort of 99 patients, including 13 diagnosed with pSOS/VOD. Hyperbilirubinemia (> 2 mg/dL) was observed in only three patients (23%), whereas transfusion-refractory thrombocytopenia, hepatomegaly, and ascites were observed in all 13 patients. When the cutoff values for HokUS-10 and HokUS-6 scores were set at 4 and 2, the respective areas under the curve were 0.977 and 0.957. The sensitivity and specificity were 100% and 80% for HokUS-10, and 77% and 97% for HokUS-6, respectively. The simplified HokUS-6 may be a practical tool for diagnosing pSOS/VOD when use of the HokUS-10 scoring system is not feasible. HokUS-10/6 is important for early detection of pSOS/VOD during regular examinations and plays a valuable role in the diagnosis of clinical pSOS/VOD. - Mature teratoma with a germinoma component presenting with undetectable placental alkaline phosphatase in cerebrospinal fluid: illustrative case
Sogo Oki; Shigeru Yamaguchi; Michinari Okamoto; Yukitomo Ishi; Hiromi Kanno-Okada; Emi Takakuwa; Yukayo Terashita; Shinsuke Hirabayashi; Kentaro Nishioka; Takayuki Hashimoto; Atsushi Manabe; Miki Fujimura
Journal of Neurosurgery: Case Lessons, 24 Feb. 2025, [Peer-reviewed]
Scientific journal - Long-term outcome and social-intellectual ability of patients with basal ganglia germinoma
Michinari Okamoto; Shigeru Yamaguchi; Ryosuke Sawaya; Yukitomo Ishi; Hiroaki Motegi; Yukayo Terashita; Minako Sugiyama; Yuko Cho; Kentaro Nishioka; Takashi Mori; Takayuki Hashimoto; Hidefumi Aoyama; Atsushi Manabe; Miki Fujimura
Pediatric Neurology, Elsevier BV, Jan. 2025
Scientific journal - Comparison of busulfan pharmacokinetics between four-times-daily and once-daily administration in pediatric patients: a preliminary prospective observational trial
Atsushi Yamaguchi; Shinsuke Hirabayashi; Kazuko Niki; Keisuke Kagami; Yukayo Terashita; Yuko Cho; Atsushi Manabe; Mitsuru Sugawara; Yoh Takekuma
International Journal of Hematology, Springer Science and Business Media LLC, 03 Dec. 2024, [Peer-reviewed]
Scientific journal - Increased response to granulocyte-macrophage colony-stimulating factor in peripheral blood cells and transient manifestations mimicking juvenile myelomonocytic leukemia in a male patient with NEMO deficiency caused by a deep intronic pathogenic variant of IKBKG.
Masahiro Ueki; Shinsuke Hirabayashi; Yoshitaka Honda; Shunichiro Takezaki; Hiroki Ohata; Shimaa Said Mohamed Ali Abdrabou; Saori Sawai; Yukayo Terashita; Yuko Cho; Hideki Muramatsu; Kazushi Izawa; Takahiro Yasumi; Yoshiyuki Takahashi; Masafumi Yamada; Atsushi Manabe
Immunological medicine, 1, 8, 01 Nov. 2024, [International Magazine]
English, Scientific journal, X-linked NF-κB essential modulator (NEMO) deficiency is a primary immunodeficiency characterized by combined immunodeficiency and ectodermal dysplasia. Monocytes from the patients demonstrate a severely impaired response to tissue necrosis factor or lipopolysaccharide, whereas hyper-inflammation is found in some patients. Juvenile myelomonocytic leukemia (JMML) is a pediatric malignancy caused by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) and aberrant RAS signaling activation. Patients with JMML demonstrate characteristic manifestations such as splenomegaly, monocytosis and the presence of myeloid or erythroid precursors in the peripheral blood. Here, we present the case of a male infant with ectodermal dysplasia, bacterial septicemia, Pneumocystis pneumonia, severe inflammation and transient manifestations mimicking JMML. Genetic analysis revealed a deep intronic germline variant of IKBKG. Full-length IKBKG cDNA and NEMO protein expression were almost inexistent. Peripheral mononuclear cells (PBMCs) from the patient showed increased RAS signaling activation with GM-CSF or Phorbol 12-myristate 13-acetate without the RAS-associated gene variant, although the increased RAS signaling activation in induced-pluripotent stem cell-derived myeloid lineage and bone marrow-derived mesenchymal cells was not evident. The patient with NEMO deficiency demonstrated JMML-like manifestation and severe inflammation. PBMCs of the patient demonstrated increased RAS signaling activation with unknown pathophysiology. - Serum 5-S-cysteinyldopa as a predictive biomarker for stem cell transplantation-related complications in children and young adults
Yukayo Terashita; Akihiro Iguchi; Minako Sugiyama; Yuko Cho; Houman Goudarzi; Isao Yokota; Atsushi Manabe
Blood Cell Therapy, Sep. 2024, [Peer-reviewed], [Lead author]
English - Survey of Transitional Care Between Pediatrics and Obstetrics/Gynecology in Japan.
Kentaro Nakamura; Yukayo Terashita; Atsushi Manabe; Nao Suzuki
Journal of adolescent and young adult oncology, 13, 3, 523, 533, Jun. 2024, [International Magazine]
English, Scientific journal, Purpose: This study's aim was to determine the actual status of transitional care for patients with pediatric cancer (PPCs) in Japan by surveying obstetricians/gynecologists. Methods: A questionnaire survey on transitional medicine was conducted in the form of an online questionnaire at 579 major training facilities nationwide, which were registered with the Japanese Society of Obstetrics and Gynecology. Results: While 40% of the facilities had received referrals for PPCs, only 13% provided transitional care specifically for PPCs. The most common problems with referrals were related to "insufficient explanation." In addition, at facilities with no experience treating PPCs, many respondents commented that they did not know how to follow the progression of the disease. Regarding the necessity of obstetrics/gynecology visits for PPCs, more than half of the respondents at facilities with experience treating PPCs answered that such visits were "necessary"; only 1% answered that they were "unnecessary." On the other hand, 37% of the facilities that had no experience treating PPCs answered that it was "necessary," whereas 4% answered that it was "unnecessary." Conclusions: This survey of the actual status of transitional care between pediatrics and obstetrics/gynecology in Japan identified issues to be addressed for the spread of transitional care. The results suggest that, in the future, health care professionals need education to increase their knowledge, and that patient education that leads to patients' awareness of their own self-management is necessary. - Treatment strategy of optic pathway hypothalamic glioma: the role of chemotherapy in recurrence
Yamaguchi Shigeru; Ishi Yukitomo; Motegi Hiroaki; Oki Sogo; Terashita Yukayo; Hasegawa Masataka; Cho Yuko; Hirabayashi Shinsuke; Manabe Atsuhi; Fujimura Miki
Nervous System in Children, 49, 3, 81, 87, The Japanese Society for Pediatric Neurosurgery, 2024
Japanese, Backgrounds: Optic pathway hypothalamic gliomas (OPHGs) are low-grade tumors, with the majority being pilocytic astrocytomas. As most cases are unresectable, a “gain time” treatment strategy should be considered until senescence of tumor growing. While the adjuvant chemotherapy may stabilize OPHG, patients occasionally experience tumor regrowth after a while. Among various treatment options for recurrence, we mainly employ repeated chemotherapy. In this study, we report the treatment outcomes of patients with OPHG at our institution.
Methods: In this retrospective study, we evaluated the treatment response of chemotherapy in recurrent OPHG cases diagnosed after 2008. Treatment responses were assessed by the best response during chemotherapy.
Results: Eighteen patients with OPHG were eligible for this study. The median age at onset was 11.5 years (range: 0-34 years). Thirteen of the 18 patients received chemotherapy for the primary tumor at onset. The median event-free survival was 29 months, and 12 of 18 patients experienced tumor recurrence. Of the patients with recurrent OPHG, eight received chemotherapy with Carboplatin (monotherapy or with Vincristine)(N=4), Temozolomide (N=3), or Vinblastine (N=1). Among the four patients who received Carboplatin, three had minor responses (defined as a <50% reduction in tumor size), and one had stable disease. Of the three patients who received Temozolomide, one achieved a minor response, one had stable disease, and one had progressive disease. The patient who received Vinblastine experienced progressive disease. Two patients who showed progressive disease on Temozolomide and Vinblastine subsequently received Carboplatin and achieved minor responses. Overall, a Carboplatin-based regimen led to objective responses in4 of 6 patients with recurrent OPHG. The median follow-up period for the study was 95.7 months (range: 10.4-182 months). To date, 13 cytoreductive surgeries have been performed in eight patients after recurrence, and two patients have received radiotherapy for disease control. One patient died of a seizure 10.4 months post onset, and one patient is currently bedridden with tumoral hemorrhage seven years post onset. The remaining patients live independently, except for two patients who were nearly blind at onset. Renal dysfunction and hearing disturbance were observed as sequelae of repeated chemotherapy in 5 and 2 patients, respectively.
Conclusion: Carboplatin-based chemotherapy demonstrated efficacy in recurrent OPHG, potentially reducing the need for surgery or deferring radiotherapy. However, the sequelae associated with the increased accumulation of chemotherapy, particularly renal dysfunction, are problematic. Effective subsequent therapies, such as molecularly targeted drugs, are desirable for a gain time strategy in patients with OPHG. - Cooperative medical system established by the Cancer Board for Pediatric Brain Tumors at Hokkaido University Hospital
Yamaguchi Shigeru; Ishi Yukitomo; Motegi Hiroaki; Terashita Yukayo; Hirabayashi Shinsuke; Hashimoto Takayuki; Manabe Atsushi; Fujimura Miki
The Japanese Journal of Pediatric Hematology / Oncology, 61, 2, 154, 158, The Japanese Society of Pediatric Hematology / Oncology, 2024
Japanese, All pediatric brain tumors are orphan diseases. As each clinician has limited experience, treatment disparities can exist for pediatric brain tumors, thus emphasizing the importance for clinicians to share information and experience in these cases.
In our institution, we have weekly meetings of the Cancer Board for Pediatric Brain Tumors to enable seamless treatment cooperation among neurosurgeons, pediatric oncologists, radiation oncologists, and other related doctors and healthcare staff. We present conditions of the patients receiving treatment, discuss treatment strategies, and adjust treatment schedules. Treatment efficacy and adverse events are objectively evaluated, leading to the provision of appropriate and expeditious treatment.
Since 2013, 161 patients aged <20 years with brain tumors have been treated; 150 cases were treated at disease onset: 28 low-grade gliomas, 22 high-grade gliomas, nine ependymomas, 27 germ cell tumors, and 21 embryonal tumors such as medulloblastomas. Overall, 128 patients underwent surgery and 70 underwent radiotherapy, mainly proton beam therapy, as primary treatment. In addition to cases of diffuse intrinsic pontine gliomas, nine (six germ cell tumors and three low-grade gliomas) were diagnosed during this meeting and received adjuvant therapy without histological confirmation by agreement. Since some patients required salvage resection for residual lesions after adjuvant therapy, the indications and timing of surgery were determined during this meeting. We usually discuss individualized treatment approaches for each patient according to age or presumed sequelae. Regular weekly cancer board meetings play a key role in treating pediatric brain tumors through multidisciplinary collaborations. - Sunburst appearanceを呈する頭蓋骨腫瘤を契機に発見された神経芽腫の1例
北川 悠; 竹中 淳規; 渡邊 史郎; 平田 健司; 内山 裕子; 木村 理奈; 中川 純一; 池辺 洋平; 長谷河 昌孝; 澤井 彩織; 寺下 友佳代; 杉山 未奈子; 平林 真介; 長 祐子; 山口 秀; 真部 淳; 工藤 與亮
北海道放射線医学雑誌, 3, 33, 36, (NPO)メディカルイメージラボ, Mar. 2023
Japanese - The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia
Jimei Zhao; Masahiro Ueki; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Ryoji Kobayashi; Yoichi Tanaka; Atsushi Manabe
EJC Paediatric Oncology, 1, 100006, 100006, Elsevier BV, 2023
Scientific journal - Central nervous system complications and white matter lesions by brain MRI in pediatric hematological malignancies
Minako Sugiyama; Shinsuke Hirabayashi; Yukayo Terashita; Yuko Cho; Akihiro Iguchi; Atsushi Manabe
30 Mar. 2022 - Hepatoblastoma with bone/bone marrow metastasis in Li-Fraumeni syndrome patient.
Masataka Hasegawa; Minako Sugiyama; Yukayo Terashita; Yuko Cho; Atsushi Manabe
Pediatrics international : official journal of the Japan Pediatric Society, 64, 1, e15135, Jan. 2022, [International Magazine]
English, Scientific journal - Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion.
Minako Sugiyama; Shinsuke Hirabayashi; Yukitomo Ishi; Junko Kikuchi; Ayako Ishikura; Hiroaki Motegi; Yuki Ueda; Saori Sawai; Kazuya Hara; Yukayo Terashita; Yuko Cho; Emi Takakuwa; Shohei Honda; Shigeru Yamaguchi; Ichiro Kinoshita; Atsushi Manabe
Pediatric blood & cancer, 68, 11, e29227, Nov. 2021, [International Magazine]
English - Diagnostic Capability of Cerebrospinal Fluid-Placental Alkaline Phosphatase Value in Intracranial Germ Cell Tumor.
Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Takashi Mori; Takayuki Hashimoto; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Akihiro Iguchi; Yuko Cho; Atsushi Manabe; Kiyohiro Houkin
Oncology, 99, 1, 23, 31, 2021, [International Magazine]
English, Scientific journal, OBJECTIVE: Most types of intracranial germ cell tumors (IGCTs) are sensitive to chemoradiation. However, biopsy specimens are usually small and thus cannot be used for obtaining an accurate pathological diagnosis. Recently, the cerebrospinal fluid (CSF) placental alkaline phosphatase (PLAP) value has been considered a new biomarker of IGCTs. The present study aimed to evaluate the discriminatory characteristics of the CSF-PLAP value upon diagnosis and at the time of recurrence in patients with IGCTs. METHODS: Between 2015 and 2019, this study included 37 patients with tumors located in the intraventricular and/or periventricular region. The CSF-PLAP level was assessed before the patients received any treatment. The PLAP level was evaluated during and after first-line chemoradiotherapy in 7 patients with IGCTs. The CSF-PLAP values were compared according to histological diagnosis, and the correlation between these values and radiographical features was assessed. The CSF-PLAP values of 6 patients with IGCTs with suspected recurrence were evaluated based on neuroimaging findings. RESULTS: The CSF-PLAP values were significantly higher in patients with IGCTs than in those with other types of brain tumor (n = 19 vs. 18; median: 359.0 vs. <8.0 pg/mL). The specificity and sensitivity were 88 and 95%, respectively, with a cutoff value of 8.0 pg/mL. In patients with IGCT, the CSF-PLAP value was higher in patients with germinoma than in those with nongerminomatous germ cell tumors (n = 12 vs. 7; median: 415.0 vs. 359.0 pg/mL). Regarding the time course, the CSF-PLAP value decreased to below the detection limit after the reception of first-line chemoradiotherapy in all 7 patients. A significant correlation was observed between the initial CSF-PLAP value and the tumor reduction volume after receiving first-line chemoradiotherapy (p < 0.0003, R2 = 0.6165, logY = 1.202logX - 1.727). Among the patients with suspected IGCT recurrence (n = 6), the CSF-PLAP value was high in patients with recurrence (n = 3; median: 259.0 pg/mL), and that in patients (n = 3) without recurrence was below the lower detection limit. CONCLUSIONS: The CSF-PLAP level is a useful biomarker during the initial diagnosis of IGCTs and at the time of recurrence. It may be associated with the volume of germinomatous components of tumors. - DIAGNOSTIC CAPABILITY OF CSF-PLAP ON INTRACRANIAL GERM CELL TUMOR
Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Yuko Cho; Akihiro Iguchi; Atushi Manabe; Kiyohiro Houkin
NEURO-ONCOLOGY, 22, 334, 334, Dec. 2020, [Peer-reviewed]
English - Refractory malignant hepatocellular tumor consisting of hepatocellular carcinoma and hepatoblastoma in a 10-year-old male
Minako Sugiyama; Shinsuke Hirabayashi; Yukayo Terashita; Yuko Cho; Akihiro Iguchi; Yoshihito Ohhara; Daisuke Abo; Shohei Honda; Emi Takakuwa; Atsushi Manabe
Authorea, Inc., 22 Jun. 2020 - Successful treatment of dumbbell-shaped Hodgkin lymphoma with massive sacral bone destruction.
Minako Sugiyama; Yukayo Terashita; Yuko Cho; Akihiro Iguchi; Ryuta Arai; Emi Takakuwa; Shohei Honda; Atsushi Manabe
Pediatric blood & cancer, 67, 5, e28210, May 2020, [Peer-reviewed], [International Magazine]
English - 発汗過多、成長障害を契機に診断に至った神経芽腫の一例
橋本 佳帆子; 中山 加奈子; 山口 健史; 原 和也; 寺下 友佳代; 杉山 未奈子; 長 祐子; 井口 晶裕; 本多 昌平; 中村 明枝; 真部 淳
臨床小児医学, 67, 1-6, 84, 89, (財)小児愛育協会, Mar. 2020
Japanese - Septic Arthritis Caused by Mycobacterium Kansasii in a Bone Marrow Transplant Recipient.
Minako Sugiyama; Yukayo Terashita; Kazuya Hara; Yuko Cho; Tsuyoshi Asano; Akihiro Iguchi
Journal of pediatric hematology/oncology, 11 Feb. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, We report an 18-year-old female individual with septic arthritis due to Mycobacterium kansasii. Three years and 6 months before arthritis, the patient underwent bone marrow transplantation and developed severe chronic graft-versus-host disease. The arthritis was refractory to medication, and she underwent joint lavage of the right foot, hip joint, and elbow joint. After surgery, her joint symptoms were relieved, and chronic graft-versus-host disease remitted more easily. It is important that we maintain a high index of suspicion for mycobacterial arthritis and diagnose it early when immunosuppressed patients experience chronic pain and joint swelling. - Immune thrombocytopenia in a case of trisomy 18.
Minako Sugiyama; Yukayo Terashita; Atsuhito Takeda; Akihiro Iguchi; Atsushi Manabe
Pediatrics international : official journal of the Japan Pediatric Society, 62, 2, 240, 242, Feb. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal - Corticosteroid-induced glaucoma in pediatric patients with hematological malignancies.
Minako Sugiyama; Yukayo Terashita; Kazuya Hara; Yuko Cho; Akihiro Iguchi; Shinki Chin; Atsushi Manabe
Pediatric blood & cancer, 66, 12, e27977, Dec. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Corticosteroids, especially dexamethasone, play a critical role in chemotherapy for pediatric hematological malignancies. We previously observed that patients with complaints of headache or photophobia during corticosteroid administration had high intraocular pressure (IOP). PROCEDURE: We measured IOP during corticosteroid administration in 15 patients with acute leukemia or lymphoma undergoing treatment at our institution from January 2016 to December 2018. IOP was measured by an ophthalmologist within seven days of the initiation of standard dose of corticosteroid, which was defined as 60 mg/m2 /day for prednisolone and 10 mg/m2 /day for dexamethasone. RESULTS: Fifteen patients received 52 courses of chemotherapy containing corticosteroids. IOP exceeded 21 mmHg among 13 patients in 28 courses. Twelve of the 13 patients were administered topical treatment, and six of the 12 patients needed additional diuretic agents. IOP during the chemotherapy courses containing dexamethasone was significantly higher compared with IOP during the chemotherapy courses containing prednisolone. Only two patients complained of symptoms, such as headache and photophobia, and one of the two patients underwent trabeculotomy. Funduscopic findings were normal in all patients. There was a dose-associated decrease in IOP with reduction of dexamethasone dose. CONCLUSIONS: IOP should be measured during administration of substantial corticosteroid doses even in patients with no symptoms. Further investigations regarding the level of IOP for intervention need to be conducted. - Outbreak of aseptic meningitis caused by echovirus 30 in Kushiro, Japan in 2017.
Yuji Maruo; Masanori Nakanishi; Yasuto Suzuki; Yosuke Kaneshi; Yukayo Terashita; Masashi Narugami; Michi Takahashi; Sho Kato; Ryota Suzuki; Akiko Goto; Masahiro Miyoshi; Hideki Nagano; Takahisa Sugisawa; Motohiko Okano
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 116, 34, 38, Jul. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Echovirus 30 (E30) is one of the most common causative agents for aseptic meningitis. OBJECTIVES: In the autumn of 2017, there was an outbreak caused by E30 in Kushiro, Hokkaido, Japan. The aim of this study was to characterize this outbreak. STUDY DESIGN: Fifty-nine patients were admitted to the Department of Pediatrics, Kushiro Red Cross Hospital (KRCH) with clinical diagnosis of aseptic meningitis. Among those, 36 patients were finally diagnosed as E30-associated aseptic meningitis by the detection of viral RNA using reverse transcription-polymerase chain reaction (RT-PCR) and/or the evidence of more than four-fold rise in neutralizing antibody (NA) titers in the convalescent phase relative to those in the acute phase. We investigated these 36 confirmed cases. RESULTS: The median age was 6 years (range: 6 months-14 years). The positive signs and symptoms were as follows: fever (100%), headache (94%), vomiting (92%), jolt accentuation (77%), neck stiffness (74%), Kernig sign (29%), and abdominal pain (28%). The median cerebrospinal fluid (CSF) white cell count, neutrophil count, and lymphocyte count were 222/μL (range: 3-1434/μL), 144/μL (range: 1-1269/μL), and 85/μL (range: 2-354/μL), respectively. Although the detected viral genes demonstrated same cluster, they were different from E30 strains observed in Japan between 2010 and 2014. CONCLUSION: We mainly showed clinical and virological features of the E30-associated aseptic meningitis outbreak that occurred in Kushiro. To prevent further spread of E30 infection, continuous surveillance of enterovirus (EV) circulation and standard precautions are considered essential. - Povidone-iodine lowers the incidence of catheter-associated bloodstream infection.
Minako Sugiyama; Akihiro Iguchi; Yukayo Terashita; Junjiro Ohshima; Yuko Cho
Pediatrics international : official journal of the Japan Pediatric Society, 61, 3, 230, 234, Mar. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Central venous (CV) catheters are required for chemotherapy but they may become a source of life-threatening infections of the bloodstream. The most effective way to disinfect the port of a CV catheter has not been established. METHODS: We report the data obtained between April 2008 and March 2010 using 83% ethanol (period I) and between April 2010 and March 2014 using 10% povidone-iodine (period II) to sterilize the access port. The participants received chemotherapy or autologous/allogeneic stem cell transplantation at the present institution. RESULTS: No significant difference was observed in patient characteristics between the two periods, such as disease, median age, or the period of neutropenia. The incidence of positive blood culture during periods I and II was 18.5% (31/168) and 11.4% (40/350; P = 0.041), respectively. The incidence of catheter-associated bloodstream infection on blood culture during periods I and II was 11.9% (20/168) and 6.3% (22/350; P = 0.043), respectively. Bacillus cereus infection was not detected during period II. CONCLUSION: The incidence of infection caused by CV catheters was significantly reduced using povidone-iodine; therefore, we recommend this procedure as part of the routine in chemotherapy. - Long-term outcome of renal function in children after stem cell transplantation measured by estimated glomerular filtration rate.
Yukayo Ukeba-Terashita; Ryoji Kobayashi; Daiki Hori; Satoru Matsushima; Hirozumi Sano; Daisuke Suzuki; Masahide Nakajima; Masahiko Suzuki; Michihiko Ueno; Shoji Fujita; Kunihiko Kobayashi
Pediatric blood & cancer, 66, 2, e27478, Feb. 2019, [Peer-reviewed], [Lead author], [International Magazine]
English, Scientific journal, BACKGROUND: Stem cell transplantation (SCT) outcomes have improved over the last three decades, with many patients being rescued with this treatment. However, improved outcomes have led to issues with long-term sequelae. One of these sequelae in children is renal dysfunction, an index of which is estimated using glomerular filtration rate (eGFR). PROCEDURE: We retrospectively analyzed eGFR in 83 pediatric patients who received SCT. Data from all patients extended up to 12 months or more post SCT. The median follow-up time was 127.7 months (range 12.0-268.8 months). RESULTS: Eighteen patients (21.7%) had low eGFR (<90 ml/min/1.73 m2 ) post SCT. Cumulative incidence of low eGFR was 25.8 ± 2.0%. Nine (10.6%) patients had a low eGFR pre-SCT. However, pre- and post-SCT incidence of low eGFR were not correlated. Meanwhile, only two patients (2.4%) exhibited severe renal dysfunction, with eGFRs < 60 ml/min/1.73 m2 . Independent risk factors for low eGFR were solid tumor and use of fludarabine. Moreover, age at SCT ≥ 7 years was also a long-term post-SCT risk factor for low eGFR in all patients. CONCLUSION: Independent post-SCT long-term risk factors for low eGFR in children were solid tumor and use of fludarabine. Moreover, age at SCT ≥ 7 years was a post-SCT long-term risk factor for low eGFR across all patients. - DICER1遺伝子変異により診断したAnaplastic Sarcoma of the Kidneyの一症例
長谷河 昌孝; 寺下 友佳代; 杉山 未奈子; 大久保 淳; 長 祐子; 井口 晶裕; 河北 一誠; 荒 桃子; 本多 昌平; 武冨 紹信; 高桑 恵美; 松野 吉宏
日本小児血液・がん学会雑誌, 55, 4, 288, 288, (一社)日本小児血液・がん学会, Oct. 2018
Japanese - Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
Akihiro Iguchi; Yuko Cho; Minako Sugiyama; Yukayo Terashita; Tadashi Ariga; Yosuke Hosoya; Shinsuke Hirabayashi; Atsushi Manabe; Keisuke Hara; Tetsuya Aiba; Tsugumi Shiokawa; Hiroko Tada; Norihiro Sato
International journal of hematology, 106, 2, 291, 298, Aug. 2017, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m2/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration-time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80%). In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib. - Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation.
Akihiro Iguchi; Yukayo Terashita; Minako Sugiyama; Junjiro Ohshima; Tomonobu Z Sato; Yuko Cho; Ryoji Kobayashi; Tadashi Ariga
Pediatric transplantation, 20, 1, 114, 9, Feb. 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal, GVHD and graft failure are serious problems in CBT. PES after CBT also occurs frequently and is associated with transplantation-related complications such as acute GVHD. We reviewed medical records for 70 consecutive child CBT recipients between December 1997 and April 2015. Forty-nine patients received prophylaxis against GVHD with CsA or Tac in combination with mPSL from day +7 (mPSL group), and 21 patients received CsA or Tac with MTX on day +1 and day +3 (MTX group). Neutrophil engraftment was detected in 59 patients (84.3%). Neutrophil engraftment rate in the MTX group was significantly higher than that in the mPSL group (21/21 (100%) and 38/49 (77.6%), respectively, p = 0.027). PES developed in 35 patients, and the incidence of PES in the mPSL group was significantly higher than that in the MTX group (p = 0.036). The incidence of severe acute GVHD (grade III or IV) in the MTX group was significantly lower than that in the mPSL group (p = 0.049). Although this study was a small-scale study, the results showed that increase in the rate of engraftment and decrease in the incidence of early immune reactions such as PES and severe acute GVHD could be achieved by early commencement of immunosuppression using MTX. - 脳原発横紋筋肉腫に対する集学的治療の経験
長 祐子; 杉山 未奈子; 寺下 友佳代; 大島 淳二郎; 佐藤 智信; 井口 晶裕; 有賀 正; 小林 浩之; 寺坂 俊介; 橋本 孝之; 高桑 恵美
日本小児血液・がん学会雑誌, 51, 4, 282, 282, (一社)日本小児血液・がん学会, Oct. 2014
Japanese - 縦隔原発神経芽腫群腫瘍の4例
工藤 絵理子; 杉山 未奈子; 寺下 友佳代; 大島 淳二郎; 佐藤 智信; 長 祐子; 井口 晶裕; 樋田 泰浩; 加賀 基知三
日本小児血液・がん学会雑誌, 51, 4, 288, 288, (一社)日本小児血液・がん学会, Oct. 2014
Japanese - 左上腕腫瘤で発症した芽球性形質細胞様樹状細胞腫瘍(BPDCN)の3歳女児例
仁平 寛子; 杉山 美奈子; 寺下 友佳代; 大島 淳二郎; 佐藤 智信; 長 祐子; 井口 晶裕; 有賀 正; 高桑 恵美; 松野 吉宏
日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号, 55回・11回・18回, 223, 223, (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会, Nov. 2013
Japanese - Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course.
Yumi Takahashi; Minako Sugiyama; Yuki Ueda; Tomoshiro Itoh; Kazuyori Yagyu; Hideaki Shiraishi; Yukayo Ukeba-Terashita; Masanori Nakanishi; Tetsuro Nagashima; Tomihiro Imai; Masakatsu Motomura; Shinji Saitoh
Brain & development, 34, 9, 784, 6, Oct. 2012, [Peer-reviewed], [International Magazine]
English, Scientific journal, Anti-muscle-specific tyrosine kinase antibody (MuSK-Ab) is the second most frequent autoantibody identified in adult patients with myasthenia gravis (MG). Adult patients with MuSK-Ab demonstrate characteristic clinical features but very little information is available for childhood-onset patients with MuSK-positive MG. We report a childhood-onset female patient with MuSK-positive MG. This patient showed basic clinical features compatible with adult-onset MuSK-positive MG, but some features, including spontaneous improvement, are distinct from those in adult patients. Serial examination of MuSK-Ab titers revealed a gross correlation with clinical severity despite significantly high titers throughout the clinical course. Therefore, childhood-onset MuSK-positive MG may demonstrate a distinct clinical characteristics in the early period of illness. - Prolonged anemia by superinfection of parvovirus B19 in a boy with enterohemorrhagic Escherichia coli O157-associated hemolytic uremic syndrome.
Keisuke Orimo; Yukayo Ukeba; Naoko Koseki; Yoshinori Saita; Ichiro Kobayashi
European journal of pediatrics, 168, 4, 501, 2, Apr. 2009, [Peer-reviewed], [International Magazine]
English, Scientific journal, We report a 3-year-old boy with enterohemorrhagic Escherichia coli (EHEC) O157-associated hemolytic uremic syndrome (HUS). His anemia was associated with decreased reticulocyte count and persisted after the recovery from HUS. Superinfection of parvovirus B19 (PVB19) was proven by a transient febrile episode associated with IgM antibodies to the virus and the delayed appearance of IgG antibodies and typical rashes. We conclude that PVB19 infection could induce severe persistent anemia in EHEC-associated HUS. Reticulocytopenia is a clue to the diagnosis in such cases. - Apnea in a 2-month-old girl with retropharyngeal abscess.
Yukayo Ukeba; Yosinori Saita; Tohru Matsuzawa; Tetsuji Wada; Naoki Kanai; Ichiro Kobayashi
Acta paediatrica (Oslo, Norway : 1992), 98, 2, 210, 210, Feb. 2009, [Peer-reviewed], [International Magazine]
English, Scientific journal
- 主要な遺伝子異常を認めない小児神経膠腫の頻度と臨床像
山口 秀; 伊師 雪友; 山本 大慈; 寺下 友佳代; 平林 真介; 種井 善一; 田中 伸哉; 長 祐子; 真部 淳; 藤村 幹, Brain Tumor Pathology, 43, Suppl., 139, 139, Jun. 2026
日本脳腫瘍病理学会, Japanese - Investigation of Secondary Findings in Comprehensive Genome Cancer Profiling Tests for Pediatric Cancer
齋藤祐介; 寺下友佳代; 平林真介; 安部樹太朗; 大浦果寿美; 長祐子; 柴田有花; 向中野実央; 藤田穂波; 有賀伸; 天野虎次; 萩尾加奈子; 山口秀; 伊師雪友; 木下一郎; 山田崇弘; 真部淳, 日本遺伝カウンセリング学会誌, 46, 2, 2025 - How should we manage multiple intracerebral hemorrhage and brain death in a patient with T-ALL?
長祐子; 澤井彩織; 原和也; 寺下友佳代; 杉山未奈子; 平林真介; 真部淳; 杉山拓; 方波見謙一; 浜崎和朗, 日本小児科学会雑誌, 126, 2, 2022 - Successful bone marrow transplantation in two sisters with activated phosphoinositide 3-kinase δ syndrome 2
M. Sugiyama; A. Iguchi; M. Yamada; Y. Terashita; J. Ohshima; Y. Cho; N. Miyake; N. Matsumoto; M. Ueki; Y. Yamazaki; S. Takezaki; I. Kobayashi; T. Ariga, Bone Marrow Transplantation, 52, 12, 1678, 1680, 01 Dec. 2017
Nature Publishing Group, English, Report scientific journal - Successful allogeneic unrelated bone marrow transplantation in a female patient with a heterozygous splice-site mutation in PIK3R1
M. Sugiyama; Y. Terashita; J. Ohshima; Y. Cho; A. Iguchi; M. Ueki; Y. Tozawa; S. Takezaki; M. Yamada; I. Kobayashi; T. Ariga, BONE MARROW TRANSPLANTATION, 51, S460, S461, Mar. 2016
English, Summary international conference - 臍帯血移植後に重篤な肺高血圧症を呈した乳児急性リンパ性白血病の1例(Severe pulmonary hypertension after cord blood transplantation for infantile acute lymphoblastic leukemia with MLL rearrangement: A case report)
寺田 健作; 大島 淳二郎; 寺下 友佳代; 杉山 未奈子; 泉 岳; 古川 卓郎; 山澤 弘州; 武井 黄太; 武田 充人; 長 祐子; 井口 晶裕; 有賀 正, 日本小児血液・がん学会雑誌, 52, 4, 246, 246, Oct. 2015
(一社)日本小児血液・がん学会, English - Graft-versus-host disease prophylaxis by early commencement of immunesuppression using methotrexate decreases pre-engraftment syndrome and accelerates engraftment after cord blood transplantation
A. Iguchi; M. Sugiyama; Y. Terashita; J. Ohshima; T. Sato; Y. Cho; T. Ariga, BONE MARROW TRANSPLANTATION, 50, S205, S206, Mar. 2015
English, Summary international conference - RISK FACTORS AND OUTCOME OF PULMONARY COMPLICATION OF PEDIATRIC PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
J. Ohshima; M. Sugiyama; Y. Terashita; T. Sato; Y. Cho; A. Iguchi; T. Ariga, BONE MARROW TRANSPLANTATION, 49, S256, S256, Mar. 2014
English, Summary international conference - Sterilization Of Catheters Using Providone-Iodine Decreases The Incidence Of Catheter-Associated Bloodstream Infection
Minako Sugiyama; Yukayo Terashita; Junjiro Ohshima; Tomonobu Sato; Yuko Cho; Akihiro Iguchi, BLOOD, 122, 21, Nov. 2013
English, Summary international conference - Neurological complications of stem cell transplantation in childhood
A. Iguchi; M. Sugiyama; Y. Terashita; J. Ohshima; T. Sato; Y. Cho; T. Ariga, BONE MARROW TRANSPLANTATION, 48, S351, S351, Apr. 2013
English, Summary international conference - Neurological Complications in Stem Cell Transplantation of Childhood
Akihiro Iguchi; Minako Sugiyama; Yukayo Terashita; Junjiro Ohshima; Yuko Cho; Tadashi Ariga, BLOOD, 120, 21, Nov. 2012
English, Summary international conference
- 基本医学研究, 2024年, 修士課程, 医学院
- 基本医学総論, 2024年, 修士課程, 医学院
- 医学総論, 2024年, 博士後期課程, 医学院
- 基盤医学研究, 2024年, 博士後期課程, 医学院
- 臨床医学研究, 2024年, 博士後期課程, 医学院
- Near-infrared photoimmunotherapy using antiGD2 antibody for unresectable cancer in childhood
Grants-in-Aid for Scientific Research
01 Apr. 2026 - 31 Mar. 2029
長 祐子; 真部 淳; 小川 美香子; 寺下 友佳代; 植木 将弘; 河原 仁守; 後藤 悠人
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 26K10771 - 北海道の小児がん患者における遺伝性素因の研究
科学研究費助成事業
01 Apr. 2023 - 31 Mar. 2026
寺下 友佳代; 真部 淳
小児がんの治療成績の改善により7割以上の患者に長期生存が期待できるようになったが、原疾患や治療に伴う晩期合併症や二次がんが問題となってきた。本研究では、北海道の小児がんの長期生存者の大規模コホートを用いて、生殖細胞系列遺伝子バリアント解析の意義を検討することを第1の目的とする。既に病的意義が明らかなバリアントについては結果を患者に原則開示するが、その際の遺伝カウンセリングの手順を確立することを第2の目的とする。
研究対象者は北海道内の病院でフォローされている小児がん患者で目標症例数は100例と設定している。設定根拠は北海道内でフォローされている小児がん患者は約1000例であり、その約1割の100例が遺伝子解析に対する同意が取得できるものと想定される。初年度は20-30例の症例集積を目標としていたが、実際に約20例の症例を集積することができた。遺伝子解析は業者に委託し、1患者あたり約5-6万円、対象遺伝子は①がん易罹患性遺伝子(Cancer predisposition genes) 常染色体顕性:ALK, APC, BRCA1, BRCA2, TP53など ②がん易罹患性遺伝子(Cancer predisposition genes) 常染色体潜性:ATM, BLM, FANCA, FANCCなど ③kinase関連遺伝子: EGFR, KITなど ④がん抑制遺伝子: AXIN1, BARD1など ⑤その他の遺伝子に分類し、計158の既知の遺伝子とした。初年度助成金は予定通り全て遺伝子解析費用として使用した。今後は今回の解析結果を臨床情報との関連性について更に解析をすすめると同時に意義のある生殖細胞系列の遺伝子バリアントを認めた症例に対して遺伝カウンセリングも進め、課題を抽出していく。また次段階の症例集積に向けて患者のリクルートをすすめていく予定である。
日本学術振興会, 基盤研究(C), 北海道大学, 23K06687
